$CBIH
Cannabis Bioscience International Holdings, Inc.

2024 Q2 Form 10-Q Financial Statement

#000168316824002587 Filed on April 22, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q2
Revenue $36.41K
YoY Change -28.96%
Cost Of Revenue $11.81K
YoY Change -51.04%
Gross Profit $24.60K
YoY Change -9.32%
Gross Profit Margin 67.57%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $184.6K
YoY Change -40.84%
Operating Profit -$160.0K
YoY Change -43.84%
Interest Expense $49.22K
YoY Change 23.71%
% of Operating Profit
Other Income/Expense, Net -$49.22K
YoY Change 23.71%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$209.2K
YoY Change -35.56%
Net Earnings / Revenue -574.53%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 10.38B shares 10.38B shares
Diluted Shares Outstanding 10.37B shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $755.00 $794.00 $8.913K
Short-Term Investments
Other Short-Term Assets $598.00 $598.00 $0.00
YoY Change
Inventory
Prepaid Expenses
Receivables $20.14K $17.04K $10.55K
Other Receivables
Total Short-Term Assets $21.49K $18.43K $19.46K
YoY Change 10.43%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $35.67K $75.54K $23.92K
YoY Change 49.12%
TOTAL ASSETS
Total Short-Term Assets $21.49K $18.43K $19.46K
Total Long-Term Assets $35.67K $75.54K $23.92K
Total Assets $57.16K $93.97K $43.38K
YoY Change 31.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $7.054K $7.054K $14.59K
YoY Change -51.66%
Total Short-Term Liabilities $881.9K $801.0K $385.5K
YoY Change 128.74%
LONG-TERM LIABILITIES
Long-Term Debt $249.4K $249.5K $249.5K
YoY Change -0.06%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $254.3K $269.0K $249.5K
YoY Change 1.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $881.9K $801.0K $385.5K
Total Long-Term Liabilities $254.3K $269.0K $249.5K
Total Liabilities $1.136M $1.070M $635.0K
YoY Change 78.91%
SHAREHOLDERS EQUITY
Retained Earnings -$5.334M -$5.198M -$4.683M
YoY Change 13.91%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.079M -$976.1K -$591.7K
YoY Change
Total Liabilities & Shareholders Equity $57.16K $93.97K $43.38K
YoY Change 31.76%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q2
OPERATING ACTIVITIES
Net Income -$209.2K
YoY Change -35.56%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q1 CBIH Related Party Receivables
RelatedPartyReceivables
0 usd
CY2023Q2 CBIH Related Party Receivables
RelatedPartyReceivables
0 usd
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
598 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
0 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
18433 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
19462 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
75541 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23920 usd
CY2024Q1 us-gaap Assets
Assets
93974 usd
CY2023Q2 us-gaap Assets
Assets
43382 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
257527 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
111299 usd
CY2024Q1 us-gaap Bank Overdrafts
BankOverdrafts
5485 usd
CY2023Q2 us-gaap Bank Overdrafts
BankOverdrafts
0 usd
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28641 usd
CY2024Q1 CBIH Related Party Payables
RelatedPartyPayables
323678 usd
CY2023Q2 CBIH Related Party Payables
RelatedPartyPayables
105173 usd
CY2024Q1 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
151267 usd
CY2023Q2 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
121407 usd
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
7054 usd
CY2023Q2 us-gaap Loans Payable Current
LoansPayableCurrent
14592 usd
CY2024Q1 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
0 usd
CY2023Q2 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
0 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
56039 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4435 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
801049 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
385547 usd
CY2024Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
249500 usd
CY2023Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
249500 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19502 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
269002 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
249500 usd
CY2024Q1 us-gaap Liabilities
Liabilities
1070052 usd
CY2023Q2 us-gaap Liabilities
Liabilities
635047 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10431749347 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10431749347 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10059677919 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10059677919 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4222068 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4091071 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5198146 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4682736 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-976078 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-591665 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93974 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43382 usd
CY2024Q1 us-gaap Revenues
Revenues
36411 usd
CY2023Q1 us-gaap Revenues
Revenues
51252 usd
us-gaap Revenues
Revenues
172979 usd
us-gaap Revenues
Revenues
270413 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
11809 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
24120 usd
us-gaap Cost Of Revenue
CostOfRevenue
35721 usd
us-gaap Cost Of Revenue
CostOfRevenue
77443 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
24602 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
27132 usd
us-gaap Gross Profit
GrossProfit
137258 usd
us-gaap Gross Profit
GrossProfit
192970 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25289 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48498 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
114012 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
102005 usd
CY2024Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
38344 usd
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
165603 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
173725 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
528610 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
95074 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
65623 usd
us-gaap Professional Fees
ProfessionalFees
202496 usd
us-gaap Professional Fees
ProfessionalFees
173767 usd
CY2024Q1 us-gaap Officers Compensation
OfficersCompensation
8000 usd
CY2023Q1 us-gaap Officers Compensation
OfficersCompensation
10735 usd
us-gaap Officers Compensation
OfficersCompensation
32000 usd
us-gaap Officers Compensation
OfficersCompensation
36235 usd
CY2024Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
17488 usd
CY2023Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
19767 usd
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
69652 usd
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
55915 usd
CY2024Q1 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
378 usd
CY2023Q1 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
1772 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
1878 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
4911 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
184573 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
311998 usd
us-gaap Operating Expenses
OperatingExpenses
593764 usd
us-gaap Operating Expenses
OperatingExpenses
901443 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-159971 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-284866 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-456506 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-708473 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
41666 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
49221 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
39789 usd
us-gaap Interest Expense
InterestExpense
58904 usd
us-gaap Interest Expense
InterestExpense
89767 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-49221 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39789 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-58904 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-48101 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-209192 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-324655 usd
us-gaap Net Income Loss
NetIncomeLoss
-515410 usd
us-gaap Net Income Loss
NetIncomeLoss
-756574 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10372408688 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10372408688 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7858525520 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7858525520 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10317612225 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10317612225 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8724596387 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8724596387 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00002
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00002
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00004
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00004
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00005
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00005
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00009
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00009
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-591665 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74997 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
19000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-181792 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-717460 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-124426 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-841886 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-209192 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-976078 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-361051 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75000 usd
CY2022Q3 CBIH Change In Value Of Common Stock
ChangeInValueOfCommonStock
0 usd
CY2022Q3 CBIH Exchange Of Common Stock For Series B Preferred
ExchangeOfCommonStockForSeriesBPreferred
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-212030 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-498081 usd
CY2022Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
312666 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-219886 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-405301 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
248300 usd
CY2023Q1 CBIH Miscellaneous Adjustment
MiscellaneousAdjustment
-2 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-324655 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-481658 usd
us-gaap Net Income Loss
NetIncomeLoss
-515410 usd
us-gaap Net Income Loss
NetIncomeLoss
-756574 usd
CBIH Adjustment For Issuance Of Common Stock Noncash Expense
AdjustmentForIssuanceOfCommonStockNoncashExpense
75000 usd
CBIH Adjustment For Issuance Of Common Stock Noncash Expense
AdjustmentForIssuanceOfCommonStockNoncashExpense
0 usd
CBIH Amortization Of Rightofuseasset And Liability
AmortizationOfRightofuseassetAndLiability
51621 usd
CBIH Amortization Of Rightofuseasset And Liability
AmortizationOfRightofuseassetAndLiability
5722 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
41666 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
71107 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7091 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1130 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
146228 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
18669 usd
CBIH Bank Overdraft Cash Flow
BankOverdraftCashFlow
5485 usd
CBIH Bank Overdraft Cash Flow
BankOverdraftCashFlow
0 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-28641 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
73646 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-304943 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-710516 usd
CBIH Etrade Investments
EtradeInvestments
0 usd
CBIH Etrade Investments
EtradeInvestments
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
75000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
635966 usd
CBIH Proceeds From Issuance Of Preferred Stock
ProceedsFromIssuanceOfPreferredStock
0 usd
CBIH Proceeds From Issuance Of Preferred Stock
ProceedsFromIssuanceOfPreferredStock
0 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
29859 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
68720 usd
CBIH Payment Of Sba Loan Current
PaymentOfSbaLoanCurrent
7539 usd
CBIH Payment Of Sba Loan Current
PaymentOfSbaLoanCurrent
497 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
19000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
218504 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
296824 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
704189 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8119 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6327 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8913 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31982 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
794 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25655 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
86767 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_zEA2WkDHxlNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zmnKGhzMfDFh">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. Certain of these estimates could be affected by external conditions, including those unique to the Company’s businesses, and general economic conditions. These external conditions could have an effect on the Company’s estimates that could cause actual results to differ materially from its estimates. Actual results could differ from those estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary. Significant estimates relied upon in preparing these statements include revenue recognition, accounts receivable reserves, accrued expenses, share-based compensation and the recoverability of the Company’s net deferred tax assets and any related valuation allowance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84C_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zWYq2riBL9E6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zPy8Ze4mXnU">Reclassification</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior consolidated financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no impact on the results of operations, changes in equity, or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.50 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Net Income Loss
NetIncomeLoss
-515410 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
304943 usd
CBIH Working Capital
WorkingCapital
-782616 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5198146 usd
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
7054 usd
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
14592 usd
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
249500 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
249500 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
256554 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
264092 usd
CY2024Q1 CBIH Operating Lease Right Of Use Asset Before Accumulated Amortization
OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization
83021 usd
CY2023Q4 CBIH Operating Lease Right Of Use Asset Before Accumulated Amortization
OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization
155387 usd
CY2024Q1 CBIH Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
7480 usd
CY2023Q4 CBIH Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
131467 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
75541 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23920 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
56039 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4435 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19502 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
75541 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4435 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
28673 usd
CY2023Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
31210 usd
CY2024Q1 us-gaap Revenues
Revenues
36411 usd
CY2023Q1 us-gaap Revenues
Revenues
51252 usd
us-gaap Revenues
Revenues
172979 usd
us-gaap Revenues
Revenues
270413 usd
us-gaap Cost Of Revenue
CostOfRevenue
35721 usd
us-gaap Cost Of Revenue
CostOfRevenue
77443 usd
CY2024Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
20010000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10431749347 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10431749347 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10059677919 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10059677919 shares
CY2024Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
5198149 usd
CY2023Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
4406729 usd
CBIH Operating Leases Rent Expense Monthly Payment
OperatingLeasesRentExpenseMonthlyPayment
3382 usd
CY2020Q3 CBIH Operating Leases Rent Expense Monthly Payment
OperatingLeasesRentExpenseMonthlyPayment
3529 usd
CY2021Q3 CBIH Operating Leases Rent Expense Monthly Payment
OperatingLeasesRentExpenseMonthlyPayment
3676 usd
CY2022Q3 CBIH Operating Leases Rent Expense Monthly Payment
OperatingLeasesRentExpenseMonthlyPayment
3823 usd
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On March 23, 2023, the Company amended the lease to extend its term to June 30, 2024, at a base rent of $4,779 per month. On September 5, 2023, the lease was amended to extend its term to June 30, 2025, at rentals of $0 per month for the two months ended November 30, 2023, $$4,779 per month for the 10 months ending June 30, 2024, and $4,926 per month for the 12 months ending June 30, 2025.
us-gaap Liabilities And Stockholders Equity Average Amount Outstanding
LiabilitiesAndStockholdersEquityAverageAmountOutstanding
323678 usd
CY2023 us-gaap Liabilities And Stockholders Equity Average Amount Outstanding
LiabilitiesAndStockholdersEquityAverageAmountOutstanding
105173 usd
us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
172979 usd
us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
270413 usd
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-002587-index-headers.html Edgar Link pending
0001683168-24-002587-index.html Edgar Link pending
0001683168-24-002587.txt Edgar Link pending
0001683168-24-002587-xbrl.zip Edgar Link pending
cannabisbio_ex1001.htm Edgar Link pending
cannabisbio_ex3100.htm Edgar Link pending
cannabisbio_ex3200.htm Edgar Link pending
cannabisbio_i10q-022924.htm Edgar Link pending
cbih-20240229.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
image_005.jpg Edgar Link pending
image_006.jpg Edgar Link pending
image_007.jpg Edgar Link pending
image_008.jpg Edgar Link pending
image_009.jpg Edgar Link pending
image_010.jpg Edgar Link pending
image_011.jpg Edgar Link pending
image_012.jpg Edgar Link pending
image_013.jpg Edgar Link pending
image_014.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
cbih-20240229_def.xml Edgar Link unprocessable
cbih-20240229_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cannabisbio_i10q-022924_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cbih-20240229_pre.xml Edgar Link unprocessable
cbih-20240229_cal.xml Edgar Link unprocessable